| Year |
Citation |
Score |
| 2017 |
Parrish-Novak J, Byrnes-Blake K, Lalayeva N, Burleson S, Fidel J, Gilmore R, Gayheart-Walsten P, Bricker GA, Crumb WJ, Tarlo KS, Hansen S, Wiss V, Malta E, Dernell WS, Olson JM, et al. Nonclinical Profile of BLZ-100, a Tumor-Targeting Fluorescent Imaging Agent. International Journal of Toxicology. 36: 104-112. PMID 28403743 DOI: 10.1177/1091581817697685 |
0.373 |
|
| 2016 |
Burge DJ, Eisenman J, Byrnes-Blake K, Smolak P, Lau K, Cohen SB, Kivitz AJ, Levin R, Martin RW, Sherrer Y, Posada JA. Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study. Lupus. PMID 27852935 DOI: 10.1177/0961203316678675 |
0.377 |
|
| 2012 |
Byrnes-Blake KA, Pederson S, Klucher KM, Anderson-Haley M, Miller DM, Lopez-Talavera JC, Freeman JA. Pharmacokinetics and pharmacodynamics of pegylated interferon lambda-1 in cynomolgus monkeys. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 32: 198-206. PMID 22280056 DOI: 10.1089/Jir.2011.0075 |
0.322 |
|
| 2010 |
Mabry R, Lewis KE, Moore M, McKernan PA, Bukowski TR, Bontadelli K, Brender T, Okada S, Lum K, West J, Kuijper JL, Ardourel D, Franke S, Lockwood L, Vu T, ... ... Byrnes-Blake K, et al. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Engineering, Design & Selection : Peds. 23: 115-27. PMID 20022918 DOI: 10.1093/Protein/Gzp073 |
0.373 |
|
| 2009 |
Ellsworth JL, Hamacher N, Harder B, Bannink K, Bukowski TR, Byrnes-Blake K, Underwood S, Oliver C, Waggie KS, Noriega C, Hebb L, Rixon MW, Lewis KE. Recombinant soluble human FcgammaR1A (CD64A) reduces inflammation in murine collagen-induced arthritis. Journal of Immunology (Baltimore, Md. : 1950). 182: 7272-9. PMID 19454724 DOI: 10.4049/Jimmunol.0803497 |
0.371 |
|
| 2008 |
Ellsworth JL, Maurer M, Harder B, Hamacher N, Lantry M, Lewis KB, Rene S, Byrnes-Blake K, Underwood S, Waggie KS, Visich J, Lewis KE. Targeting immune complex-mediated hypersensitivity with recombinant soluble human FcgammaRIA (CD64A). Journal of Immunology (Baltimore, Md. : 1950). 180: 580-9. PMID 18097060 DOI: 10.4049/Jimmunol.180.1.580 |
0.367 |
|
| 2007 |
Milesi-Hallé A, McMillan DE, Laurenzana EM, Byrnes-Blake KA, Owens SM. Sex differences in (+)-amphetamine- and (+)-methamphetamine-induced behavioral response in male and female Sprague-Dawley rats. Pharmacology, Biochemistry, and Behavior. 86: 140-9. PMID 17275894 DOI: 10.1016/J.Pbb.2006.12.018 |
0.465 |
|
| 2005 |
Byrnes-Blake KA, Laurenzana EM, Landes RD, Gentry WB, Owens SM. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. European Journal of Pharmacology. 521: 86-94. PMID 16182279 DOI: 10.1016/J.Ejphar.2005.08.016 |
0.547 |
|
| 2003 |
Laurenzana EM, Byrnes-Blake KA, Milesi-Hallé A, Gentry WB, Williams DK, Owens SM. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 1320-6. PMID 14570763 DOI: 10.1124/Dmd.31.11.1320 |
0.56 |
|
| 2003 |
Byrnes-Blake KA, Laurenzana EM, Carroll FI, Abraham P, Gentry WB, Landes RD, Owens SM. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. European Journal of Pharmacology. 461: 119-28. PMID 12586207 DOI: 10.1016/S0014-2999(03)01313-X |
0.564 |
|
| 2001 |
Byrnes-Blake KA, Carroll FI, Abraham P, Owens SM. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. International Immunopharmacology. 1: 329-38. PMID 11360933 DOI: 10.1016/S1567-5769(00)00019-9 |
0.53 |
|
| Show low-probability matches. |